Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent children's cancer group studies

Journal of Clinical Oncology

Volumn 14, Issue 9, 1996, Pages 2417-2426

  Stram, D O ^a   Matthay, K K ^a   O'Leary, M ^a   Reynolds, C P ^a   Haase, G M ^a   Atkinson, J B ^a   Brodeur, G M ^a   Seeger, R C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROBLASTOMA; ONCOGENE C MYC; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0029758492     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.9.2417     Document Type: Article

References (56)

1. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
2. Seeger RC, Reynolds CP: Neuroblastoma, in Holland JF, Frei E III, Bast RC Jr, et al (eds): Cancer Medicine. Philadelphia, PA, Lea & Febiger, 1993, pp 2172-2184
3. Hayes FA, Smith EI: Neuroblastoma. in Pizzo PA, Poplack DG (eds): Principles and Practices of Pediatric Oncology (ed 1). Philadelphia, PA, Lippincott, 1989, pp 607-622
4. Bonilla MA, Cheung NK: Clinical progress in neuroblastoma. Cancer Invest 12:644-653, 1994
5. Hann HW, Evans AE, Siegel SE, et al: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Childrens Cancer Study Group experience. Cancer Res 45:2843-2848, 1985
6. Breslow N, McCann B: Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31:2098-2103, 1971
7. Finklestein JZ, Klemperer MR, Evans AE, et al: Multiagent chemotherapy for children with metastastic neuroblastoma: A report from the Children's Cancer Study Group. Med Pediatr Oncol 6:179-188, 1979
8. Evans AE, D'Angio GJ, Propert K, et al: Prognostic factors in neuroblastoma. Cancer 59:1853-1859, 1987
9. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
10. Rosen EM, Cassady JR, Frantz CN, et al: Neuroblastoma: The Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/ Children's Hospital experience. J Clin Oncol 2:719-732, 1984
11. Castleberry RP: Clinical and biologic features in the prognosis and treatment of neuroblastoma. Curr Opin Oncol 4:116-123, 1992
12. Seeger RC, Reynolds CP: Neuroblastomas, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Cambridge, Blackwell Scientific, 1994, pp 814-826
13. Matthay KK, Seeger RC, Reynolds CP, et al: Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Children's Cancer Group. J Clin Oncol 12:2382-2389, 1994
14. Seeger RC, Reynolds CP: Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 38:393-424, 1991
15. Philip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1037-1044, 1991
16. Cheung NV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
17. Pole JG, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:152-158, 1991 (erratum, 9:1094, 1991)
18. Kushner BH, O'Reilly RJ, LaQuaglia M, et al: Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer 66:1095-1100, 1990
19. Hartmann O, Benhamou E, Beaujean, et al: Repeated highdose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 5:1205-1211, 1987
20. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607-2613, 1994
21. Kushner BH, O Reilly RJ, Mandell LR, et al: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9:274-279, 1991
22. Berthold F, Burdach S, Kremens B, et al: The role of chemotherapy in the treatment of children with neuroblastoma stage IV: The GPO (German Pediatric Oncology Society) experience. Klin Padiatr 202:262-269, 1990
23. Bernard JL, Philip T, Zucker JM, et al: Sequential cisplatin/ VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: An effective alternating non-cross-resistant regimen? J Clin Oncol 5:1952-1959, 1987
24. Hayes FA, Green AA, Casper J, et al: Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: Response and toxicity. Cancer 48:1715-1718, 1981
25. Ikeda K, Nakagawara A, Yano H, et al: Improved survival rates in children over 1 year of age with stage III or IV neuroblastoma following an intensive chemotherapeutic regimen. J Pediatr Surg 24:189-193, 1989
26. Nitschke R, Cangir A, Crist W, et al: Intensive chemotherapy for metastatic neuroblastoma: A Southwest Oncology Group study. Med Pediatr Oncol 8:281-288, 1980
27. Shafford EA, Rogers DW, Pritchard J: Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 2:742-747, 1984
28. Bowman LC, Hancock ML, Santana VM, et al: Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St Jude Children's Research Hospital experience, 1962 to 1988. J Clin Oncol 9:1599-1608, 1991
29. Suita S, Zaizen Y, Kaneko M, et al: What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma. J Pediatr Surg 29:746-750, 1994
30. Crowley J, Hu M: Covariance analysis of heart transplant survival data. J Am Stat Assoc 72:27-36, 1977
31. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma: Children's Cancer Study group A. Cancer 27:374-378, 1971
32. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
33. Reynolds CP, Seeger RC, Vo DD, et al: Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 46:5882-5886, 1986
34. Seeger RC, Reynolds CP, Vo DD, et al: Depletion of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res 175:443-458, 1985
35. Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219-226, 1991
36. Moss TJ, Fonkalsrud EW, Feig SA, et al: Delayed surgery and bone marrow transplantation for widespread neuroblastoma. Ann Surg 206:514-520, 1987
37. Haase GM, O'Leary MC, Ramsay NK, et al: Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 26:1119-23, 1991
38. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
39. Breslow N: Covariance analysis of censored survival data. Biometrics 30:89-99, 1974
40. Stram DO, Matthay KK, O'Leary M, et al: Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma, in Evan EA, Biedler JL, Brodeur GM, et al (eds): Advances in Neuroblastoma Research 4, Proceedings of the Sixth Symposium on Advances in Neuroblastoma Research, Philadelphia, PA, May 13-15, 1993. New York, NY, Wiley-Liss, 1994
41. Matthay KK, O'Leary MC, Ramsay NK, et al: Role of Myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 31A:572-575, 1995
42. Kushner BH, Cheung NK: Neuroblastoma. Pediatr Ann 17:269-278, 1988
43. Matthay KK, Atkinson JB, Stram DO, et al: Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Children's Cancer Group pilot study. J Clin Oncol 11:2226-2233, 1993
44. Seeger RC, Villablanca JG, Matthay KK, et al: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 366:527-533, 1991
45. Pinkerton CR: ENSG I-randomised study of high-dose melphalan in neuroblastoma. Bone Marrow Transplant 7:112-113, 1991 (suppl 3)
46. Shuster JJ, Cantor AB, McWilliams N, et al: The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 9:1045-1049, 1991
47. Ohnuma N, Takahashi H, Kaneko M, et al: Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med Pediatr Oncol 24:181-187, 1995
48. Nakagawara A, Arima-Nakagawara M, Azar CG, et al: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52:1364-1368, 1992
49. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993
50. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85:377-384, 1993
51. Chan HS, Haddad G, Thorner PS, et al: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614, 1991
52. Bourhis J, Benard J, Hartmann O, et al: Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 81:1401-1405, 1989
53. Leone A, Seeger RC, Hong CM, et al: Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 8:855-865, 1993
54. Hailat N, Keim DR, Melhem RF, et al: High levels of p19/ nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 88:341-345, 1991
55. Mattano LA, Moss TJ, Emerson SG: Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 52:4701-4705, 1992
56. Seeger RC, Moss TJ, Feig SA, et al: Bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 271:203-213, 1988